Akari Therapeutics Plc · NASDAQ:AKTX
Akari Therapeutics — Investor Presentation (February 2025)
26 slides from Akari Therapeutics's investor presentation, February 2025
Slide 1: Next-Generation Precision Bi-Functional Antibody Drug Conjugates
Corporate Presentation Next-Generation Precision Bi-Functional February 2025 Antibody Drug Conjugates NASDAQ: AKTX akaritx.com
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation includes expressed or implied forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act), about the Akari Therapeutics, Plc
Slide 3: We Are Akari Therapeutics
WE ARE AKARI THERAPEUTICS Akari Therapeutics is an innovative targeted oncology company built on next-generation ADCs and a novel discovery engine 3
Slide 4: Why Akari
Why Akari Lead Candidate AKTX-101 (TROP2 PH1 ADC) Significant advantages over current TROP2 ADCs Innovative Precision Antibody Drug observed in multiple preclinical models: Conjugates (ADCs) for the - Superior activity Treatment of Cancer - Prolonged survival - Less resistance - Better tolerability
Slide 5: ADCs Have Revolutionized Cancer Therapy, But Have Some Shortcomings
2023 Sales from Approved ADCs ADCs Have Revolutionized Product Toxin Class 2023 Sales Cancer Therapy, But DNA Damaging Agent DNA Damaging Agent $1.0B $2.7B Have Some Shortcomings Solid Tumors Microtubule Inhibitor <$100M Microtubule Inhibitor $1.75B Microtubule Inhibitor $1.3B All Currently Approved
Slide 6: Bi-Functional ADC Platform Targeting Cancer
Bi-Functional ADC Platform Targeting Cancer Highly Selective Cancer Cell Death Combined With Enhanced Immune System Engagement for Effective Tumor Eradication Antibody Linker Payload Targeting Clinically Connects Anti-Tumor Payload Differentiated Novel PH1 Payload Validated TROP2 Receptor to Targeti
Slide 7: Next-Generation Precision ADC Pipeline
Next-Generation Precision ADC Pipeline Program Indication Discovery Preclinical Clinical Highlights • Novel Payload: PH1 AKTX-101 • Advancing IND-enabling (TROP2 PH1 ADC) Solid Tumors preclinical studies ADC with Novel Payload • Pursue licensing / strategic partnership • Novel Payload: PH5 AKTX-102
Slide 8: Akari Platform Technology Can Fuel a Pipeline
Akari Platform Technology Can Fuel a Pipeline Ability to Precisely Tune Assets for Purpose Allows for Multiple Program Development for Additional Licensing Partnerships Application Targeting Antibody Proprietary Linkers Anti-Cancer Payload Lung Cancer CD20 Lys-L92 Colorectal Cancer Nectin-4 Lys-L91
Slide 9: Novel PH1 Payload: Superior Activity Across Tumor Types and Targets
Novel PH1 Payload: Superior Activity With Potent Effect Across Various Tumors Types and Targets Using Platform Technology In Vitro Studies Performed at Lower PH1 Drug Dose (Lower DAR) Gastric Trop2High Bladder Trop2Heterogenous Pancreatic Trop2High 100 100 100 Trop2 PH1 (DAR4) Trop2 PH1 (DAR4) Trop2
Slide 10: AKTX-101: Novel Payload is a Spliceosome Inhibitor
AKTX-101: Novel Payload is a Spliceosome Inhibitor With Multiple Anti-Tumor Mechanisms Novel Anti-Cancer Payload That Disrupts RNA Splicing Within Cancer Cells, Inducing Tumor-Specific Cell Death While Generating Immunostimulatory Effects and Minimizing Off-Target Toxicity Potential to Overcome Shor
Slide 11: AKTX-101: Direct Tumor Cell Cytotoxicity and Generation of Neoantigens
AKTX-101: Direct Tumor Cell Cytotoxicity and Generation of Neoantigens Bi-Functional Payload Targeting the Spliceosome Bi-functional results of PH1 targeted splicing 1 PH1 ADC binds MHC Neoantigen to the target PH1 receptor. TUMOR CELL MEMBRANE TROP2 Neoantigen formation can stimulate the immune res
Slide 12: Immune Response to Payload-Induced Neoantigens Extends Beyond ADC Target
AKTX-101: PH1 ADC Immune Response to Payload-Induced Neoantigens Extends Target receptor Beyond ADC Target Receptor (Her2 or Trop2) Cancer neoepitope Myeloid cell Activation T cell Activation B cell Payload induced neoepitope TCR T cells recognize neoantigens and become B cells recognize neoantigens
Slide 13: PH1 Payload Treated Mice Retained Immune Memory and Rejected Rechallenge
PH1 Payload Treated Mice Retained Immune Memory and Rejected Rechallenge with Tumor Cells Potent Synergy With Checkpoint Inhibitor PH1 Induced Tumor-Specific Has Potential to Cure Colorectal Tumors Immune Memory ADC Treatment and Survival Curves Rechallenge MC38-hHer2 ADC Doses MC38-hHer2 B16-F10 Tu
Slide 14: AKTX-101: Novel Payload is a Spliceosome Inhibitor
AKTX-101: Novel Payload is a Spliceosome Inhibitor With Multiple Anti-Tumor Mechanisms Novel Anti-Cancer Payload That Disrupts RNA Splicing Within Cancer Cells, Inducing Tumor-Specific Cell Death While Generating Immunostimulatory Effects and Minimizing Off-Target Toxicity Potential to Overcome Shor
Slide 15: AKTX-101: Demonstrated Reduced Off-Target Toxicity in Preclinical Study
AKTX-101: Demonstrated Reduced Normal Human Fibroblasts Off-Target Toxicity in TROP2none Preclinical Study Limited effect on Normal Human Fibroblasts, an example of off-target toxicity of Trodelvy® Proprietary Linker Only Releases PH1 Payload Upon Cell Internalization – No Leakage Suggests Potential
Slide 16: AKTX-101: Overcomes Resistance Mechanisms
AKTX-101: Novel Payload is a Spliceosome Inhibitor With Multiple Anti-Tumor Mechanisms Novel Anti-Cancer Payload That Disrupts RNA Splicing Within Cancer Cells, Inducing Tumor-Specific Cell Death While Generating Immunostimulatory Effects and Minimizing Off-Target Toxicity Potential to Overcome Shor
Slide 17: AKTX-101: Shown to Avoid Development of Resistance in Preclinical Study
AKTX-101: Shown to Avoid 120 Development of Resistance in 100 % Live Cells 80 Preclinical Study 60 40 MES-SA MES-SA/MX2 PH1 MES-SA/MX2 + PH1 Payload is Designed to Evade MDR Transporter Efflux 20 Elacridar Pumps and is unaffected by mutations in Tubulin or DNA 0 0.0001 0.01 1 100 10000 Damage Pathwa
Slide 18: AKTX-101: Potential for Synergy With Immunotherapies
AKTX-101: Novel Payload is a Spliceosome Inhibitor With Multiple Anti-Tumor Mechanisms Novel Anti-Cancer Payload That Disrupts RNA Splicing Within Cancer Cells, Inducing Tumor-Specific Cell Death While Generating Immunostimulatory Effects and Minimizing Off-Target Toxicity Potential to Overcome Shor
Slide 19: AKTX-101 Anti-Tumor Activity and Improved Survival With Standard of Care I/O
AKTX-101 Demonstrated Anti-Tumor Activity and Improved Overall Survival in Combination With Standard of Care I/O Mouse Bladder Syngeneic Cancer Tumor Model (Urothelial) Expressing Human TROP2 Protein Superior Anti-Tumor Efficacy In Superior Overall Survival Combination With IO Combination With IO hT
Slide 20: Significant Big Pharma Interest and Deal Flow in Early-Stage ADCs
Significant Big Pharma Interest and Deal Flow in Early-Stage ADCs Licensee Licensor Phase Asset Target Date Deal Type Upfront Payment Total Deal Highlights Preclinical 1 ADC Undisclosed 1/2025 Licensing $47M $47M upfront + $1.16B total milestones and royalties Research collaboration and license agre
Slide 21: Proven Management Team
Proven Management Team Samir R. Patel, MD Torsten Hombeck, PhD Miles Nunn, D. Phil Satyajit Mitra, PhD Chief Executive Officer Chief Financial Officer Chief Scientific Officer Executive Director, Head of Oncology Serial entrepreneur with more Seasoned executive with over Accomplished scientist and d
Slide 22: Highly Experienced, Involved, Knowledgeable Board
Highly Experienced, Involved, Knowledgeable Board to Help Steer Strategy and Execution Hoyoung Huh, MD, PhD Samir R. Patel, MD Ray Prudo, MD Chairman Chief Executive Officer Director Founder of Peak Bio Inc. and has held CEO since December of 2024, founder and principal Founder, Chairman, and CEO of
Slide 23: Upcoming Expected Value Driving Milestones
Upcoming Expected Value Driving Milestones Building a Next-Generation Legacy Pipeline Precision Bi-Functional ADC Platform Assets Ongoing and Near-Term Ongoing • Present anticipated PH1 Payload Preclinical Data at Scientific Conference BD Efforts To Secure • Complete additional IND-enabling preclini
Slide 24: Assets Beyond ADC Platform
Assets Beyond ADC Platform Opportunity for Non-Dilutive Capital Through Ongoing BD Activities to Secure Development Partner for Inactive Programs Global Market Program Indication Discovery Preclinical Phase 1 Phase 2 Phase 3 Opportunity PAS-Nomacopan Long-Acting Complement C5 & Geographic Atrophy $2
Slide 25: Why Now
Why Now Next-Generation Precision Antibody Drug Conjugates (ADC) Candidates for the Treatment of Cancer Innovative Bi-Functional ADC Platform Technology Customizable Targets by Tumor, Novel Payloads, Unique Linkers to Generate a Pipeline of Superior ADCs for Out-Licensing Opportunities AKTX-101 (TRO
Slide 26: Investor Relations
Investor Relations Next-Generation Precision Bi-Functional JTC Team aktx@jtcir.com Antibody Drug Conjugates (908) 824-0775
Akari Therapeutics — Investor Presentation (February 2025) on 6ix